USFDA completes inspection at Strides Pharma Science’s Bangalore facility
20th Jul 2019

Strides Pharma Science’s formulations facility in Bangalore has underwent a US Food and Drug Administration (USFDA) inspection that ended on May 24, 2019. The inspection was completed successfully with a Voluntary Action Indicated (VAI) classification.

The flagship facility in Bangalore is the largest manufacturing facility for the company with capabilities to  produce  finished  dosage  formulation  products  across  multiple  dosage  formats  including  tablet, capsules, ointments, creams and liquids. The facility services the key regulated markets of the US, Europe, and Australia. 

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.